Salute e Benessere

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides…

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today.Conference call and webcast scheduled for January 31, 2025, at 09:00 (CET). Link to webcast here .Fourth Quarter 2024 Business UpdateHighlightsOn December 17, 2024, Ultimovacs announced an agreement to combine its business with Zelluna Immunotherapy AS and the...
Nasdaq GlobeNewswire
31/01/2025

Novartis continues strong momentum of sales growth with margin expansion…

Ad hoc announcement pursuant to Art. 53 LR Full yearNet sales grew +12% (cc 1, +11% USD) with core operating income1 up +22% (cc, +19% USD)Sales growth driven by continued strong performance fromEntresto(+31% cc),Cosentyx(+25% cc),Kesimpta(+49% cc),Kisqali(+49% cc),Pluvicto(+42% cc) andLeqvio(+114% cc)Core operating income margin 138.7%, +330 basis points (cc), mainly driven by higher net sales Operating income grew +55% (cc, +49% USD); net...
Nasdaq GlobeNewswire
31/01/2025

Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning…

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report Discover which therapies are expected to grab the major MASH market share @Metabolic Dysfunction-Associated Steatohepatitis Market Report Metabolic Dysfunction-Associated Steatohepatitis Overview Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from...
PR Newswire
30/01/2025

South Texas Blood and Tissue Center First US Civilian Blood Center to Install…

The FrontlineODP™ system produces "on demand" spray dried plasma, a revolutionary solution for transfusion in environments where conventional plasma products (often frozen) are unavailable or logistically challenging to use. Velico's proprietary spray drying manufacturing process creates a powdered plasma product that is stable at ambient temperature, can be reconstituted with sterile water and is ready for transfusion in approximately 2 ½ minutes. This technology is anticipated to…
PR Newswire
30/01/2025

Saudi Hospitals Advance in Brand Finance's 2025 Rankings

RIYADH, Saudi Arabia, Jan.30, 2025(GLOBE NEWSWIRE) -- Saudi hospitals have made significant strides in the 2025 Brand Finance global ranking of the world's Top 250 hospitals, with seven Saudi hospitals making the list, including two in the top 100 globally. Leading the rankings regionally, King Faisal Specialist Hospital & Research Centre climbed to 15th place globally, improving from 20th place over the past two years, maintaining its position as the top healthcare institution in...
Nasdaq GlobeNewswire
30/01/2025

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a…

Saint Herblain (France), January 30, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO ®. Under this new one-year contract, the DoD will buy a minimum of $32.8 million worth of IXIARO ®vaccines and has the possibility to purchase additional doses during the coming twelve...
Nasdaq GlobeNewswire
30/01/2025

Sleep Software Market to Hit USD 1,569.2 Million by 2030 with 10.1% CAGR |…

Browse in-depth TOC on "Sleep Software Market" Browse in-depth TOC on "Sleep Software Market" 350 - Tables150 - Figures400 - Pages Integrating telehealth and mHealth solutions drives significant growth in the sleep software market by enhancing accessibility, improving user engagement, and facilitating comprehensive care delivery. Telehealth platforms enable remote consultations with sleep specialists, streamlining diagnosis and treatment pathways, particularly in...
PR Newswire
30/01/2025

UroMems Welcomes Medical Device Technology Leader Dan Rose as New Board Chairman

"We are very pleased to welcome Dan as our new board chair at this very exciting time for the company," said UroMems co-founder and CEO Hamid Lamraoui. "His proven track record in the industry and dynamic leadership capabilities position him extremely well as UroMems moves forward with our next phase of large-scale U.S. and European pivotal clinical trials of UroActive®, preparing for the commercial launch of the first smart automated artificial urinary sphincter (AUS) to treat…
PR Newswire
30/01/2025

Orion and Invenra announce discovery service and commercial license agreement to…

ORION CORPORATIONPRESS RELEASE30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using...
Nasdaq GlobeNewswire
30/01/2025

Vertiv and Johnson Controls Take the Lead in ABI Research's Thermal Management…

Vertiv took the overall lead, benefiting from the first mover advantage through the dedicated AI DC portfolio Vertiv360, leveraging its strong ecosystem partnerships with Nvidia and Intel. In addition, its scaled global deployments demonstrated Vertiv's expertise in thermal management hardware, software for critical infrastructure, and allied services like power, IT equipment, and servicing efficient DCs. Johnson Controls, a fierce competitor of Vertiv, is a leader in the implementation criteria…
PR Newswire
30/01/2025

Sagility acquires BroadPath Healthcare Solutions, a US healthcare focused…

The acquisition of BroadPath aligns with Sagility's strategy to diversify its client base and add new capabilities to its services portfolio. This acquisition significantly expands Sagility's market presence, adding more than 30 new clients. It further strengthens Sagility's position among the top ten largest health plans in the US. In addition, the acquisition gives Sagility the opportunity to cross-sell its broad service offerings to several mid-market clients including payers, third-party…
PR Newswire
30/01/2025

Evaxion announces pricing of $10.8 million public offering

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs.MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc...
Nasdaq GlobeNewswire
30/01/2025

uniQure Announces Favorable Recommendation from Independent Data Monitoring…

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~~ Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Jan.30, 2025(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Independent Data Monitoring...
Nasdaq GlobeNewswire
30/01/2025

SciBase continues US expansion, on-boards Several US Dermatology Practices that…

"To date, evaluating atypical moles at point-of-care to assess and guide biopsy decisions remains challenging, even for experienced dermoscopists. Early melanomas and even some invasive melanomas can have very few morphologic features, which make it challenging to assess at point-of-care. The Nevisense tests is non-invasive and provides us with important cellular data from below the skin surface before we make our biopsy decision, enabling improved atypical mole management for our…
PR Newswire
30/01/2025

Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New…

Ciril Faia, CEO SPECT Europe for Curium commented,“We are delighted with the expansion of our partnership with Izotop which will enable Curium to offer Iodine-131 solutions for both diagnostic and treatment purposes in Europe. This is particularly important given the recent concern across Europe's nuclear medicine industry about the contracting availability of I-131 products. The recent investment in our Petten production facilities combined with our partnership with Izotop is another...
Nasdaq GlobeNewswire
30/01/2025

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial…

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV)Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trialPrimary completion expected H2 2025 NEW YORK and VIENNA, Jan.30, 2025(GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the...
Nasdaq GlobeNewswire
30/01/2025

LifeArc Ventures 2024: new investments, targeted follow-ons and substantive…

"We continue to see strong opportunities to invest in life sciences companies in the UK and globally, and we look forward to helping our companies grow, and continuing to invest in new companies in 2025." "We continue to see strong opportunities to invest in life sciences companies in the UK and globally, and we look forward to helping our companies grow, and continuing to invest in new companies in 2025." Expanding the portfolio in therapeutics and medtech LifeArc…
PR Newswire
30/01/2025

Kinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to…

David Harris, President and CEO of Kinectrics, expressed his excitement about the new agreement: "We are extremely pleased to partner with Isotopia in providing the critical isotope Gadolinium-160 to support their production of Terbium-161. After years of research and development as well as significant investment, Kinectrics is proud to be producing highly enriched stable isotopes for the radiopharmaceutical industry. This agreement removes a key bottleneck to advancing Tb-161-based…
PR Newswire
30/01/2025

Zymeworks Announces Participation in Upcoming Investor Conferences

Oppenheimer 35 thAnnual Healthcare Life Sciences Conference: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on February 11 at 11:20 am Eastern Time (ET).Citi's 2025 Virtual Oncology Leadership Summit: Zymeworks' management will participate in a virtual fireside chat on February 20 at 2:00 pm ET.B. Riley Securities Precision Oncology & Radiopharma Conference: Zymeworks' management will participate in one-on-one meetings and a panel...
Nasdaq GlobeNewswire
30/01/2025

Comanche Biopharma Awarded Innovation Passport Designation by the U.K…

ILAP aims to accelerate time to market, facilitating faster patient access to clinically important and promising medicines being developed to address significant health needsPreeclampsia is a serious obstetric complication that threatens the life of both mother and baby, often resulting in preterm deliveryGlobally, preeclampsia is a leading cause of maternal and infant morbidity and mortality and can result in lifelong consequencesA novel investigational drug candidate, CBP-4888...
Nasdaq GlobeNewswire
30/01/2025

Connect America joins Fractus' licensee network in the healthcare sector

"We are thrilled to welcome Connect America as part of the Fractus family," said Fractus CEO Jordi Ilario. "This agreement not only solidifies our presence in the medical/health sector but also underscores our dedication to empowering industries with robust and reliable antenna solutions. Together with Connect America, we are contributing to a safer and more connected world." "We are thrilled to welcome Connect America as part of the Fractus family," said Fractus…
PR Newswire
30/01/2025

The Freedom International Group, an investment company focusing on technology…

2024 Facts & Figures 2024 Facts & Figures The leading business on the group is Project V, focused on nutraceuticals for health, wellness and beauty. " Project V totaled a record revenue level of130 million USD" said Sirakanyan, " and by the end of 2025 we target to reach150 million USDin revenues. The Project V business was enriched in fall by the introduction of GH, a drinking complex in ampoules based on 6-year-old white imperial Ginseng. Now Project V offers 80…
PR Newswire
30/01/2025

Proposals of the Shareholders' Nomination Board of Bioretec Ltd to the Annual…

The Shareholders' Nomination Board proposes to the Annual General Meeting that the following remuneration be paid to the Board members for the term starting at the end of the Annual General Meeting and ending at the end of the Annual General Meeting in 2026: The Shareholders' Nomination Board proposes to the Annual General Meeting that the following remuneration be paid to the Board members for the term starting at the end of the Annual General Meeting and ending at the end of the...
PR Newswire
30/01/2025

Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people…

"2024 was a highly impactful year for the Novo Nordisk Foundation," says Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation. "In addition to projects funded, we launched new international collaborations and expanded our geographical presence beyond Denmark." "2024 was a highly impactful year for the Novo Nordisk Foundation," saysMads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation. "In addition to projects funded, we launched new international…
PR Newswire
30/01/2025
Altri  Comunicati